Summary Genetic Signatures Ltd (Genetic Signatures) formerly Human Genetic Signatures Pty Ltd, is a molecular diagnostics company.The company designs and manufactures real-time polymerase chain reaction (PCR) based products for the detection of infectious diseases under the EasyScreen brand.
It offers EasyScreen multiplex real-time PCR pathogen detection kits; and MethylEasy kits for DNA bisulphite modification.Genetic Signatures’ product pathogen detection kits provide hospital and pathology laboratories with the molecular tools to screen for infectious pathogens in a rapid and high-throughput environment.
The company transforms molecular diagnostics using streamlined sample processing methods linked to multiplexed real-time PCR screening assays. Genetic Signatures is headquartered in Newtown, New South Wales, Australia.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope: - The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments - The report analyzes all pipeline products in development for the company Genetic Signatures Ltd - The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status) - The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date - The report provides detailed description of products in development, technical specification and functions - The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy: - Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape - Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio - To formulate effective Research & Development strategies - Develop market-entry and market expansion strategies - Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc - Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Our reports have been used by over 10K customers, including:
129 pages •
By Global Industry Analysts
• Aug 2021
Abstract: The ongoing Covid-19 pandemic has highlighted the potential for mRNA therapies. The mRNA technology has experienced decades of research efforts from scientists and various biotechnology companies. Discovered in the 1960s as an option to convert DNA codes into proteins, mRNA took several decades to emerge...
The global apheresis equipment market exhibited strong growth during 2015-2020. Looking forward, the analyst expects the market to grow at a CAGR of 8.8% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic...
The human microbiome market is expected to reach US$ 2,921.68 million by 2028 from US$ 718.95 million in 2021; it is estimated to grow at a CAGR of 22.2% during 2021-2028. The market growth is mainly attributed to factors such as the increasing incidence of lifestyle diseases, rising focus on human microbiome therapies, and growing...
269 pages •
By The Business Research Company
• Aug 2021
Anatomic Pathology Equipment and Consumables Market Opportunities And Strategies To 2030: COVID-19 Growth And Change provides the strategists, marketers and senior management with the critical information they need to assess the global anatomic pathology equipment and consumables market as it emerges from the COVID 19 shut down. Description: Where...
Respiratory Syncytial Virus Prophylaxis - Global Drug Forecast and Market Analysis to 2030 Summary Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense RNA orthopneumovirus belonging to the family of Pneumoviridae.The most common clinical scenario for RSV is an...
Interleukin 1 (IL1) - Drugs in Development, 2021 Summary According to the recently published report ’Interleukin 1 - Drugs in Development, 2021’; Interleukin 1 (IL1) pipeline Target constitutes close to 36 molecules. Out of which approximately 35 molecules are developed by companies and remaining...
The Asia Pacific organoids market is expected to reach US$ 513.74 million in 2027 from US$ 97.02 million in 2019. The market is estimated to grow at a CAGR of 23.1% from 2020 to 2027. Rising adoption of biobanking and tumor modelling and alternatives for animal testing models acting as kingpins are expected to augment the growth of the...
Melanoma - Global Drug Forecast and Market Analysis to 2029 Summary Melanoma of the skin is a serious and aggressive form of cancer originating from melanocytes, the pigment cells in skin, and can develop anywhere on the body.Although melanoma has high survivability, it remains a significant health...
The Europe organoids market is projected to reach US$ 1,260.08 million by 2027 from US$ 247.85 million in 2019; it is estimated to grow at a CAGR of 22.5% from 2020 to 2027. Increasing demand for tumor modelling and biobanking and rising adoption of personalized drugs are expected to drive the market. Personalized medicine is a growing...
The Middle East & Africa organoids market is expected to reach US$ 141.26 million in 2027 from US$ 37.34 million in 2019; the market is estimated to grow at a CAGR of 20.9% from 2020 to 2027. The growth of the market can be attributed to growing research on organoids in the Middle East & Africa region and rising focus on developing alternatives...
Chronic Disease Prevalence
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.